OrbiMed’s Phathom Pharmaceuticals PHAT Stock Holding History

OrbiMed’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,449,073	Closed	-$26.2M	–	133
2024 Q3	$26.2M	Buy	+1,449,073	New	+$20.3M	0.48%	53

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed's PHAT Position: Q4 2024 in Review

OrbiMed sold out of Phathom Pharmaceuticals (PHAT) in Q4 2024, closing a stake of 1,449,073 shares — an estimated $26.2M sold.

OrbiMed first reported a position in PHAT in Q3 2024 and held it in 1 quarter. The position peaked at $26.2M in Q3 2024. 144 funds tracked by Wall St. Rank hold PHAT as of Q4 2024.

OrbiMed reported no remaining Phathom Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
OrbiMed sold 1,449,073 Phathom Pharmaceuticals shares in Q4 2024, an estimated $26.2M.
OrbiMed first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 1 quarter.
OrbiMed's Phathom Pharmaceuticals position peaked at $26.2M in Q3 2024.
144 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.